BAG3 Down-Modulation Reduces Anaplastic Thyroid Tumor Growth by Enhancing Proteasome-Mediated Degradation of BRAF Protein
Context:Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis through multiple mechanisms.Objective:The objective of the study was the investigation of the influence of B-cell lymphoma-2-associate...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 97; no. 1; pp. E115 - E120 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.01.2012
Copyright by The Endocrine Society |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Context:Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis through multiple mechanisms.Objective:The objective of the study was the investigation of the influence of B-cell lymphoma-2-associated athanogene 3 (BAG3) on ATC growth.Design and Subjects:We investigated the effects of BAG3 down-modulation, obtained by using a specific small interfering RNA, on in vitro and in vivo growth of the human ATC cell line 8505C. Because BRAF protein plays an important role in ATC cell growth, we analyzed the effects of BAG3 down-modulation on BRAF protein levels. Furthermore, by using a proteasome inhibitor, we verified whether BAG3-mediated regulation of BRAF levels involved a proteasome-dependent mechanism.Results:BAG3 down-modulation significantly inhibits ATC growth in vitro and in vivo. BAG3 coimmunoprecipitates with BRAF protein, and its down-modulation results in a significant reduction of BRAF protein levels, which can be reverted by incubation with the proteasome inhibitor MG132.Conclusion:BAG3 protein sustains ATC growth in vitro and in vivo. The underlying molecular mechanism appears to rely on BAG3 binding to BRAF, thus protecting it from proteasome-dependent degradation. These results are in line with the reported ability of BAG3 to interfere with the proteasomal delivery of a number of other client proteins. |
---|---|
AbstractList | Context:Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis through multiple mechanisms.Objective:The objective of the study was the investigation of the influence of B-cell lymphoma-2-associated athanogene 3 (BAG3) on ATC growth.Design and Subjects:We investigated the effects of BAG3 down-modulation, obtained by using a specific small interfering RNA, on in vitro and in vivo growth of the human ATC cell line 8505C. Because BRAF protein plays an important role in ATC cell growth, we analyzed the effects of BAG3 down-modulation on BRAF protein levels. Furthermore, by using a proteasome inhibitor, we verified whether BAG3-mediated regulation of BRAF levels involved a proteasome-dependent mechanism.Results:BAG3 down-modulation significantly inhibits ATC growth in vitro and in vivo. BAG3 coimmunoprecipitates with BRAF protein, and its down-modulation results in a significant reduction of BRAF protein levels, which can be reverted by incubation with the proteasome inhibitor MG132.Conclusion:BAG3 protein sustains ATC growth in vitro and in vivo. The underlying molecular mechanism appears to rely on BAG3 binding to BRAF, thus protecting it from proteasome-dependent degradation. These results are in line with the reported ability of BAG3 to interfere with the proteasomal delivery of a number of other client proteins. Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis through multiple mechanisms.CONTEXTAnaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis through multiple mechanisms.The objective of the study was the investigation of the influence of B-cell lymphoma-2-associated athanogene 3 (BAG3) on ATC growth.OBJECTIVEThe objective of the study was the investigation of the influence of B-cell lymphoma-2-associated athanogene 3 (BAG3) on ATC growth.We investigated the effects of BAG3 down-modulation, obtained by using a specific small interfering RNA, on in vitro and in vivo growth of the human ATC cell line 8505C. Because BRAF protein plays an important role in ATC cell growth, we analyzed the effects of BAG3 down-modulation on BRAF protein levels. Furthermore, by using a proteasome inhibitor, we verified whether BAG3-mediated regulation of BRAF levels involved a proteasome-dependent mechanism.DESIGN AND SUBJECTSWe investigated the effects of BAG3 down-modulation, obtained by using a specific small interfering RNA, on in vitro and in vivo growth of the human ATC cell line 8505C. Because BRAF protein plays an important role in ATC cell growth, we analyzed the effects of BAG3 down-modulation on BRAF protein levels. Furthermore, by using a proteasome inhibitor, we verified whether BAG3-mediated regulation of BRAF levels involved a proteasome-dependent mechanism.BAG3 down-modulation significantly inhibits ATC growth in vitro and in vivo. BAG3 coimmunoprecipitates with BRAF protein, and its down-modulation results in a significant reduction of BRAF protein levels, which can be reverted by incubation with the proteasome inhibitor MG132.RESULTSBAG3 down-modulation significantly inhibits ATC growth in vitro and in vivo. BAG3 coimmunoprecipitates with BRAF protein, and its down-modulation results in a significant reduction of BRAF protein levels, which can be reverted by incubation with the proteasome inhibitor MG132.BAG3 protein sustains ATC growth in vitro and in vivo. The underlying molecular mechanism appears to rely on BAG3 binding to BRAF, thus protecting it from proteasome-dependent degradation. These results are in line with the reported ability of BAG3 to interfere with the proteasomal delivery of a number of other client proteins.CONCLUSIONBAG3 protein sustains ATC growth in vitro and in vivo. The underlying molecular mechanism appears to rely on BAG3 binding to BRAF, thus protecting it from proteasome-dependent degradation. These results are in line with the reported ability of BAG3 to interfere with the proteasomal delivery of a number of other client proteins. CONTEXT:Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis through multiple mechanisms. OBJECTIVE:The objective of the study was the investigation of the influence of B-cell lymphoma-2-associated athanogene 3 (BAG3) on ATC growth. DESIGN AND SUBJECTS:We investigated the effects of BAG3 down-modulation, obtained by using a specific small interfering RNA, on in vitro and in vivo growth of the human ATC cell line 8505C. Because BRAF protein plays an important role in ATC cell growth, we analyzed the effects of BAG3 down-modulation on BRAF protein levels. Furthermore, by using a proteasome inhibitor, we verified whether BAG3-mediated regulation of BRAF levels involved a proteasome-dependent mechanism. RESULTS:BAG3 down-modulation significantly inhibits ATC growth in vitro and in vivo. BAG3 coimmunoprecipitates with BRAF protein, and its down-modulation results in a significant reduction of BRAF protein levels, which can be reverted by incubation with the proteasome inhibitor MG132. CONCLUSION:BAG3 protein sustains ATC growth in vitro and in vivo. The underlying molecular mechanism appears to rely on BAG3 binding to BRAF, thus protecting it from proteasome-dependent degradation. These results are in line with the reported ability of BAG3 to interfere with the proteasomal delivery of a number of other client proteins. Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis through multiple mechanisms. The objective of the study was the investigation of the influence of B-cell lymphoma-2-associated athanogene 3 (BAG3) on ATC growth. We investigated the effects of BAG3 down-modulation, obtained by using a specific small interfering RNA, on in vitro and in vivo growth of the human ATC cell line 8505C. Because BRAF protein plays an important role in ATC cell growth, we analyzed the effects of BAG3 down-modulation on BRAF protein levels. Furthermore, by using a proteasome inhibitor, we verified whether BAG3-mediated regulation of BRAF levels involved a proteasome-dependent mechanism. BAG3 down-modulation significantly inhibits ATC growth in vitro and in vivo. BAG3 coimmunoprecipitates with BRAF protein, and its down-modulation results in a significant reduction of BRAF protein levels, which can be reverted by incubation with the proteasome inhibitor MG132. BAG3 protein sustains ATC growth in vitro and in vivo. The underlying molecular mechanism appears to rely on BAG3 binding to BRAF, thus protecting it from proteasome-dependent degradation. These results are in line with the reported ability of BAG3 to interfere with the proteasomal delivery of a number of other client proteins. |
Author | De Simone, Veronica Chiappetta, Gennaro Pezzullo, Luciano Basile, Anna De Laurenzi, Vincenzo Botti, Gerardo Califano, Daniela Conforti, Daniela Rea, Domenica Turco, Maria Caterina Arra, Claudio Pasquinelli, Rosa Barbieri, Antonio Giudice, Aldo Losito, Simona |
AuthorAffiliation | Functional Genomic Unit (G.C., D.C., R.P., V.D.S.), Animal Facility (C.A., A.B., D.R., A.G.), Thyroid and Parathyroid Surgery (L.P.), and Pathology Department (G.B., S.L.), National Cancer Institute, Fondazione G. Pascale, 80131 Naples, Italy; Department of Pharmaceutical Sciences (A.B., D.C., M.C.T.), University of Salerno, 84084 Fisciano, Italy; and Department of Biomedical Sciences (V.D.L.), University of Chieti-Pescara, 66100 Chieti, Italy |
AuthorAffiliation_xml | – name: Functional Genomic Unit (G.C., D.C., R.P., V.D.S.), Animal Facility (C.A., A.B., D.R., A.G.), Thyroid and Parathyroid Surgery (L.P.), and Pathology Department (G.B., S.L.), National Cancer Institute, Fondazione G. Pascale, 80131 Naples, Italy; Department of Pharmaceutical Sciences (A.B., D.C., M.C.T.), University of Salerno, 84084 Fisciano, Italy; and Department of Biomedical Sciences (V.D.L.), University of Chieti-Pescara, 66100 Chieti, Italy |
Author_xml | – sequence: 1 givenname: Gennaro surname: Chiappetta fullname: Chiappetta, Gennaro email: chiappetta.gennaro@gmail.com organization: 1Functional Genomic Unit (G.C., D.C., R.P., V.D.S.),80131 Naples, Italy – sequence: 2 givenname: Anna surname: Basile fullname: Basile, Anna organization: 2Animal Facility (C.A., A.B., D.R., A.G.), 80131 Naples, Italy – sequence: 3 givenname: Claudio surname: Arra fullname: Arra, Claudio organization: 2Animal Facility (C.A., A.B., D.R., A.G.), 80131 Naples, Italy – sequence: 4 givenname: Daniela surname: Califano fullname: Califano, Daniela organization: 1Functional Genomic Unit (G.C., D.C., R.P., V.D.S.),80131 Naples, Italy – sequence: 5 givenname: Rosa surname: Pasquinelli fullname: Pasquinelli, Rosa organization: 1Functional Genomic Unit (G.C., D.C., R.P., V.D.S.),80131 Naples, Italy – sequence: 6 givenname: Antonio surname: Barbieri fullname: Barbieri, Antonio organization: 2Animal Facility (C.A., A.B., D.R., A.G.), 80131 Naples, Italy – sequence: 7 givenname: Veronica surname: De Simone fullname: De Simone, Veronica organization: 1Functional Genomic Unit (G.C., D.C., R.P., V.D.S.),80131 Naples, Italy – sequence: 8 givenname: Domenica surname: Rea fullname: Rea, Domenica organization: 2Animal Facility (C.A., A.B., D.R., A.G.), 80131 Naples, Italy – sequence: 9 givenname: Aldo surname: Giudice fullname: Giudice, Aldo organization: 2Animal Facility (C.A., A.B., D.R., A.G.), 80131 Naples, Italy – sequence: 10 givenname: Luciano surname: Pezzullo fullname: Pezzullo, Luciano organization: 3Thyroid and Parathyroid Surgery (L.P.), 80131 Naples, Italy – sequence: 11 givenname: Vincenzo surname: De Laurenzi fullname: De Laurenzi, Vincenzo organization: 6Department of Biomedical Sciences (V.D.L.), University of Chieti-Pescara, 66100 Chieti, Italy – sequence: 12 givenname: Gerardo surname: Botti fullname: Botti, Gerardo organization: 4Pathology Department (G.B., S.L.), National Cancer Institute, Fondazione G. Pascale, 80131 Naples, Italy – sequence: 13 givenname: Simona surname: Losito fullname: Losito, Simona organization: 4Pathology Department (G.B., S.L.), National Cancer Institute, Fondazione G. Pascale, 80131 Naples, Italy – sequence: 14 givenname: Daniela surname: Conforti fullname: Conforti, Daniela organization: 1Functional Genomic Unit (G.C., D.C., R.P., V.D.S.),80131 Naples, Italy – sequence: 15 givenname: Maria Caterina surname: Turco fullname: Turco, Maria Caterina organization: 5Department of Pharmaceutical Sciences (A.B., D.C., M.C.T.), University of Salerno, 84084 Fisciano, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22072743$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kt1r2zAUxcXoWNNub3segj3sZer0Zct-TL-yQctGyWBvQpGua2eOlEo2If_9lLrboFAhIQl-53B1j07QkQ8eEHrP6BnjjH5Z2zNOGSNUVvIVmrFaFkSxWh2hGaWckVrxX8foJKU1pUzKQrxBx5xTxZUUM7Q_ny8Evgw7T26DG3szdMHjO3CjhYTn3mx7k4bO4mW7j6FzeDluQsSLGHZDi1d7fOVb423n7_GPGAYwKWyA3ILrzAAOX8J9NG4yDQ0-v5tfT1zn36LXjekTvHvaT9HP66vlxVdy833x7WJ-Q6yoC0qcqq1pVMOboljVTSWV40ZWFqBWtChXQgnJwVFHocqHsuGOlbwqeVmCtLQQp-jT5LuN4WGENOhNlyz0vfEQxqRrJkslKKOZ_PiMXIcx-lycFqyUUqiiOPh9eKLG1Qac3sZuY-Je_-1pBj5PgI0hpQjNP4RRfYhMr60-RKYPkWWcP8NtNzx2bIim618SyUm0C_0AMf3uxx1E3YLph1bTPPKjKpIFeeYbyauk_3sRxu1LVT1-JPEHaxazLA |
CitedBy_id | crossref_primary_10_1038_s41416_021_01446_2 crossref_primary_10_1038_cddis_2014_32 crossref_primary_10_1172_JCI149415 crossref_primary_10_1016_j_taap_2022_116067 crossref_primary_10_1007_s12032_016_0862_5 crossref_primary_10_1016_j_bbcan_2012_06_001 crossref_primary_10_1007_s13273_017_0010_0 crossref_primary_10_1097_CCO_0b013e32835c1381 crossref_primary_10_3390_ijms24119148 crossref_primary_10_1038_cddis_2016_321 crossref_primary_10_1002_cbin_12199 crossref_primary_10_3390_biomedicines10081994 crossref_primary_10_1186_s12885_018_4657_2 crossref_primary_10_1002_1878_0261_12492 crossref_primary_10_4161_15384101_2014_952959 crossref_primary_10_18632_oncotarget_23858 crossref_primary_10_18632_oncotarget_9039 crossref_primary_10_1016_j_bbagen_2020_129628 crossref_primary_10_1016_j_semcdb_2017_08_049 crossref_primary_10_1155_2019_9734576 crossref_primary_10_18632_oncotarget_2261 crossref_primary_10_1371_journal_pone_0226199 crossref_primary_10_1210_jc_2014_1779 crossref_primary_10_18632_oncotarget_18902 crossref_primary_10_1016_j_pharmthera_2020_107498 crossref_primary_10_3390_cancers14174168 crossref_primary_10_1186_1297_9716_44_61 |
ContentType | Journal Article |
Copyright | Copyright © 2012 by The Endocrine Society 2012 Copyright © 2012 by The Endocrine Society |
Copyright_xml | – notice: Copyright © 2012 by The Endocrine Society 2012 – notice: Copyright © 2012 by The Endocrine Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
DOI | 10.1210/jc.2011-0484 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | E120 |
ExternalDocumentID | 22072743 10_1210_jc_2011_0484 00004678-201201000-00060 10.1210/jc.2011-0484 |
Genre | Research Support, Non-U.S. Gov't Journal Article Report |
GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ H~9 KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 .GJ 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ ABDPE ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AERZD AFFNX AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU EIHJH FEDTE FYUFA HMCUK HVGLF IAO IHR INH ITC J5H M1P MBLQV N4W NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 WHG X52 ZGI ZXP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3950-d79caf7f2f55b9f847d2a48cee97056b37342ed0d0e842e6f2d16286266e4c053 |
ISSN | 0021-972X 1945-7197 |
IngestDate | Fri Jul 11 16:02:30 EDT 2025 Mon Jun 30 12:43:06 EDT 2025 Thu Apr 03 07:08:29 EDT 2025 Tue Jul 01 00:49:54 EDT 2025 Thu Apr 24 23:08:49 EDT 2025 Fri May 16 04:03:20 EDT 2025 Fri Feb 07 10:35:39 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3950-d79caf7f2f55b9f847d2a48cee97056b37342ed0d0e842e6f2d16286266e4c053 |
Notes | SourceType-Scholarly Journals-1 content type line 14 ObjectType-Report-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
PMID | 22072743 |
PQID | 3164437555 |
PQPubID | 2046206 |
ParticipantIDs | proquest_miscellaneous_914673010 proquest_journals_3164437555 pubmed_primary_22072743 crossref_primary_10_1210_jc_2011_0484 crossref_citationtrail_10_1210_jc_2011_0484 wolterskluwer_health_00004678-201201000-00060 oup_primary_10_1210_jc_2011-0484 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20120101 2012-January 2012-01-00 2012-Jan |
PublicationDateYYYYMMDD | 2012-01-01 |
PublicationDate_xml | – month: 01 year: 2012 text: 20120101 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2012 |
Publisher | Oxford University Press Copyright by The Endocrine Society |
Publisher_xml | – name: Oxford University Press – name: Copyright by The Endocrine Society |
SSID | ssj0014453 |
Score | 2.1943734 |
Snippet | Context:Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell... CONTEXT:Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell... Anaplastic thyroid tumors (ATC) express high levels of BAG3, a member of the BAG family of cochaperone proteins that is involved in regulating cell apoptosis... |
SourceID | proquest pubmed crossref wolterskluwer oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | E115 |
SubjectTerms | Adaptor Proteins, Signal Transducing - antagonists & inhibitors Adaptor Proteins, Signal Transducing - genetics Adaptor Proteins, Signal Transducing - metabolism Adaptor Proteins, Signal Transducing - physiology Animals Apoptosis Apoptosis Regulatory Proteins B-cell lymphoma Cell Growth Processes - genetics Cell Line, Tumor Down-Regulation - genetics Female Gene Expression Regulation, Neoplastic - drug effects Humans Lymphocytes B Mice Mice, Nude Molecular modelling Proteasome Endopeptidase Complex - drug effects Proteasome Endopeptidase Complex - metabolism Proteasome Endopeptidase Complex - physiology Proteasome inhibitors Proteasomes Protein Binding - drug effects Proteins Proteolysis - drug effects Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism RNA, Small Interfering - pharmacology siRNA Thyroid Thyroid Carcinoma, Anaplastic Thyroid gland Thyroid Neoplasms - genetics Thyroid Neoplasms - metabolism Thyroid Neoplasms - pathology Up-Regulation - drug effects Up-Regulation - genetics Xenograft Model Antitumor Assays |
Title | BAG3 Down-Modulation Reduces Anaplastic Thyroid Tumor Growth by Enhancing Proteasome-Mediated Degradation of BRAF Protein |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201201000-00060 https://www.ncbi.nlm.nih.gov/pubmed/22072743 https://www.proquest.com/docview/3164437555 https://www.proquest.com/docview/914673010 |
Volume | 97 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXKkBAIIb4pDOQHeJoy5cNumsdudBug8oA6aW-REztrx5pUaaOq_EP-FffabpKOVWK8RFFrJY7viX2uc8-9hHzk0Dvex2R4PAscBgzbEa6AF4_7kvFA9GWCQuHR997ZOft6wS86nd-tqKVqmRymv27VlfyPVeE3sCuqZO9g2fqi8AOcg33hCBaG4z_Z-GhwGgAFXuXOqJC2DhcMmKwwzGqQizlQY0zIOp6sy2IqD8bVrChxu2m1nCDvHOYTTLeRX6JeAKy9KGbKGeniHQoDlC9LIWtKefRjcGLa2WTdVw3QWvknaqmlymUBU1LeJHmaqSVA7nqTtFAHFUzFHHi7obCnMOmLsmg2VxdTE-yMWZ4bZOrKSFjNs5LTurHWmAldR9zK5kV7Q0NHhrQ3NI6L-VpvTOA44CMMbXfVJpC1PZ9jgEmoC7LX87mJ993CrZmch55RjtqFfuhpGd7fiwh4wbiIpIdm_9gkW72Zlls7V7DSO_gIrmcF-j33Hrnvg8eCxTQ-f_lWf9BizCZEtR22GgwUULVvtMWOthSXLcfnEXm8KjCWYvFTSylahGj8lDyxngwdGFg-Ix2VPycPRjZW4wVZIzrpDXRSi07aoJNadFKNTmrQSZM1rdFJb0EnbaGTFhlFdFKLzpfk_GQ4Pj5zbKEPJw0i7joyjFKRhZmfcZ5EGRAm6QvWB_4WhUDQkyAMmK-kK13Vh5Ne5ksPJdVALhVLYRl5RfbyIldvCIWBToB08swTKZNemHgsUT1gYEnEeoq7XXKwGeA4tVnwsRjLdYzeMJgjvkpjNEeM5uiST3Xrucn-sqMdBVvtauKYJvsbQ8b2pVzEgQfuSBByzuEK9d8wweNXO5GrolrEEXIZWIah66-N_ev7-L4L7gcLusTZAkRsNNTxLoy-vWP7d-Rh86Luk71lWan3wMWXyQeN8j_kytof |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BAG3+Down-Modulation+Reduces+Anaplastic+Thyroid+Tumor+Growth+by+Enhancing+Proteasome-Mediated+Degradation+of+BRAF+Protein&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Chiappetta%2C+Gennaro&rft.au=Basile%2C+Anna&rft.au=Arra%2C+Claudio&rft.au=Califano%2C+Daniela&rft.date=2012-01-01&rft.pub=Copyright+by+The+Endocrine+Society&rft.issn=0021-972X&rft.volume=97&rft.issue=1&rft.spage=E115&rft.epage=E120&rft_id=info:doi/10.1210%2Fjc.2011-0484&rft.externalDocID=00004678-201201000-00060 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |